Hydromorphone: Difference between revisions
Ostermayer (talk | contribs) (Text replacement - "Category:Drugs" to "Category:Pharmacology") |
Elcatracho (talk | contribs) |
||
| (6 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: | *Type: [[Opioids]] | ||
*Dosage Forms: PO, SC, IM, IV, PR | *Dosage Forms: PO, SC, IM, IV, PR, PCA | ||
*Common Trade Names: Dilaudid, Exalgo | *Common Trade Names: Dilaudid, Exalgo | ||
==Adult Dosing== | ==Adult Dosing== | ||
=== | ===Severe Pain=== | ||
*Oral: 2-4mg PO q4-6h PRN | |||
*0. | *IV: 0.2-1mg IV q2-3h PRN | ||
*IM: 1-2mg IM q2-3h PRN (not recommended secondary to variable absorption) | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
Pain | ===Severe Pain=== | ||
> 6 months, > 50 kg: 0.5 - | *> 6 months, > 50 kg: 0.5 - 2mg PO/SC/IM/IV q3-6h. | ||
*Alternatively: 15-20 mcg/kg q3-6h. | |||
==Special Populations== | ==Special Populations== | ||
| Line 27: | Line 28: | ||
*Allergy to class/drug | *Allergy to class/drug | ||
*Respiratory depression | *Respiratory depression | ||
* [[CNS depression]] | |||
* MAO inhibitor use in prior 2 weeks | |||
* GI obstruction or ileus | |||
==Adverse Reactions== | ==Adverse Reactions== | ||
| Line 33: | Line 37: | ||
*Apnea | *Apnea | ||
*Hypotension | *Hypotension | ||
* | *Syncope | ||
* | *Bradycardia | ||
* | *Urinary retention | ||
*Seizures | *Seizures | ||
* | *[[Anaphylaxis]] | ||
===Common=== | ===Common=== | ||
| Line 54: | Line 58: | ||
*Excretion: urine | *Excretion: urine | ||
*Mechanism of Action:binds to various opioid receptors | *Mechanism of Action:binds to various opioid receptors | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
Latest revision as of 01:01, 21 February 2021
General
- Type: Opioids
- Dosage Forms: PO, SC, IM, IV, PR, PCA
- Common Trade Names: Dilaudid, Exalgo
Adult Dosing
Severe Pain
- Oral: 2-4mg PO q4-6h PRN
- IV: 0.2-1mg IV q2-3h PRN
- IM: 1-2mg IM q2-3h PRN (not recommended secondary to variable absorption)
Pediatric Dosing
Severe Pain
- > 6 months, > 50 kg: 0.5 - 2mg PO/SC/IM/IV q3-6h.
- Alternatively: 15-20 mcg/kg q3-6h.
Special Populations
- Pregnancy Rating: C
- Lactation Risk Categories: probably safe
- Renal Dosing
- Adult: mod-severe impairment: decrease start dose, amount not defined
- Pediatric: mod-severe impairment: decrease start dose, amount not defined
- Hepatic Dosing
- Adult: Child-pugh class B: decrease start dose 50-75%
- Pediatric: Child-pugh class B:decrease start dose 50-75%
Contraindications
- Allergy to class/drug
- Respiratory depression
- CNS depression
- MAO inhibitor use in prior 2 weeks
- GI obstruction or ileus
Adverse Reactions
Serious
- Respiratory Depression
- Apnea
- Hypotension
- Syncope
- Bradycardia
- Urinary retention
- Seizures
- Anaphylaxis
Common
- Nausea
- Rash
- Headache
- Fatigue
- xerostomia
- constipation
- Tremor
- urinary retention
Pharmacology
- Half-life: 2.3 hour
- Metabolism: Liver
- Excretion: urine
- Mechanism of Action:binds to various opioid receptors